TPP: Australia succeeds in limiting data exclusivity to five years

Australia’s government has said the period of data exclusivity available for biological drugs in the Trans-Pacific Partnership (TPP) will be five years, despite pressure from the US to extend it to 12.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia-Pacific

Australia boutique hires experienced life sciences litigator

23 February 2023 New recruit joins from DLA Piper and will head up firm’s litigation team | Previously worked on Pfizer v Samsung Bioepis, Jusand v Rattlejack & Murray Engineering, and Pfizer v Sandoz | Follows prosecutor Chris Vindurampulle who joined in October last year.

Asia-Pacific

Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent

24 May 2022 The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.

Asia-Pacific

Wyeth secures Australian injunction against MSD vaccine

30 November 2020 The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.

More features

Edwards v Meril: Behind the UPC’s landmark medtech showdown

Bird & Bird targets Nordic life sciences growth with regulatory hire

PTAB year in review: A shifting landscape and outlook for 2026

UPC: A review of 2025 and what to expect in 2026

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

TPP: Australia succeeds in limiting data exclusivity to five years

More on this story

Editor's picks

Editor's picks

More features